Global Celiac Disease Drugs Market Size study & Forecast, by Drugs (First Line of Treatment and Second Line of Treatment) and Regional Analysis, 2022-2029

Global Celiac Disease Drugs Market Size study & Forecast, by Drugs (First Line of Treatment and Second Line of Treatment) and Regional Analysis, 2022-2029

Global Celiac Disease Drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Celiac Disease or celiac sprue or gluten-sensitive enteropathy is a digestive problem that affects small intestine. Consumption of gluten triggers an immune response in the small intestine. There are different symptoms of Celiac disease including diarrhoea, bloating, wind, fatigue, low blood count (anaemia) and osteoporosis among others. The increasing incidence of Celiac Disease and growing investments in celiac disease awareness programs are key factors driving the market growth.

The increasing prevalence of Celiac Disease is contributing towards the expansion of Global Celiac Disease Treatment Market. For instance – as per Beyond Celiac Organization – in the United States an estimated 1 in 133 Americans, or about 1% of the population, has celiac disease. Moreover, as per the University of Chicago Medicine’s Celiac disease Center estimates – in USA Celiac disease affects at least 3 million Americans. Also, increasing investment in healthcare sector in developing region and rising R&D activities related to celiac disease drugs would create lucrative growth prospectus for the market over the forecast period. However, stringent regulatory framework for drug approval stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Celiac Disease Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and increasing incidences of celiac diseases in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and the growing healthcare sector in the region.

Major market player included in this report are:
F. Hoffmann-La Roche
Merck & Co., Inc.
Johnson & Johnson
BiolineRx Ltd.
Pfizer Inc.
Innovate Biopharmaceuticals
ImmusanT, Inc.
Novartis AG
Bristol-Myers Squibb Company
Immunomedics, Inc.

Recent Developments in the Market:
 In August 2019, the US Food and Drug Administration (FDA) approved an investigational new drug (IND) for oral ActoBiotics AG017 capsules from ActoBio Therapeutics. This new drug is an oral biologic drug candidate for the reversal of celiac disease.

Global Celiac Disease Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drugs, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drugs
First Line of Treatment
Second Line of Treatment

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

F. Hoffmann-La Roche
Merck & Co., Inc.
Johnson & Johnson
BiolineRx Ltd.
Pfizer Inc.
Innovate Biopharmaceuticals
ImmusanT, Inc.
Novartis AG
Bristol-Myers Squibb Company
Immunomedics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.